Definium Therapeutics Inc. Common Shares vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while iShares 0 3 Month Treasury Bond ETF trades at $100.47 (market cap $114.04B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 24.2× Definium Therapeutics Inc. Common Shares's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| DFTX | SGOV | |
|---|---|---|
Market Cap | $4.71B | $114.04B |
Volume | 1,966,636 | 19,563,576 |
Sector | Health | Fixed Income |
52-Week High | $48.45 | $100.72 |
52-Week Low | $10.68 | $100.28 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $3.67B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.465 with minimal daily movement, reflecting its stable Treasury bill focus. The ETF shows bearish technical signals with 17 sell indicators versus 4 buys, though RSI levels suggest potential oversold conditions. Recent institutional selling by Envestnet Asset Management (-13.2% in Q2 2026) contrasts with consistent dividend distributions around $0.30-0.31 monthly.
SGOV provides stable income exposure to short-term US Treasuries amid rising bond yields, but faces headwinds from the ongoing bond market rout. The ETF's defensive positioning appeals to income-focused investors, though continued yield increases could pressure near-term performance. Current technical weakness suggests cautious entry points may emerge.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →